Overview
Retatrutide is classified as a triple agonist (glp-1/gip/glucagon) peptide. Superior body recomposition, massive fat loss, metabolic health.
Multi-receptor activation for appetite suppression, fat oxidation, energy expenditure. Unique triple agonism at GLP-1, GIP, and glucagon receptors delivers synergistic metabolic effects unmatched by single or dual agonists.
Also known as: LY3437943
Category
Triple Agonist (GLP-1/GIP/Glucagon)
Half-Life
144h
Route
SubQ
FDA Status
Not Approved
How Does Retatrutide Work?
Multi-receptor activation for appetite suppression, fat oxidation, energy expenditure. Unique triple agonism at GLP-1, GIP, and glucagon receptors delivers synergistic metabolic effects unmatched by single or dual agonists.
At the molecular level, Retatrutide operates through pathways characteristic of the Triple Agonist (GLP-1/GIP/Glucagon) class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Retatrutide Phase 2 trial: ~24% weight loss at 48 weeks
Jastreboff et al. (NEJM): Phase 2 RCT showing 24.2% body weight reduction at 12mg dose over 48 weeks the highest reported weight loss in any obesity drug trial to date.
Evidence: strong[2]Retatrutide Phase 1 safety and dose-dependent weight loss
First-in-human Phase 1 trial demonstrating dose-dependent weight loss, favorable safety profile, and significant HbA1c reductions across multiple dose levels.
Evidence: moderate[3]Retatrutide reduces liver fat (MASLD Phase 2a sub-study)
Randomized Phase 2a sub-study (n=98, Nature Medicine 2024): retatrutide 12mg achieved 82.4% relative liver fat reduction at 24 weeks, with 86% of participants normalizing liver fat (<5%). At 48 weeks in the broader Phase 2 trial, 89–93% of participants on 8–12mg doses achieved steatosis resolution.
Evidence: strong[4]Triple GLP-1/GIP/glucagon agonism pharmacological rationale
Review of the triple agonism mechanism: GLP-1 provides appetite suppression, GIP enhances GH-like metabolic effects, and glucagon drives energy expenditure and hepatic lipid oxidation.
Evidence: moderate[5]GIPR:GCGR co-agonism restores normal weight in obese rodents.
A 2026 study demonstrated that a novel GIPR:GCGR co-agonist lacking GLP-1 activity successfully reduced excess body weight and improved glycemia in obese rodents. Researchers found that correcting obesity without GLP-1 agonism could potentially avoid the gastrointestinal adverse effects commonly associated with current treatments.
Evidence: preclinical[6]Development of the Weight and Emotions Scale (WES).
A 2026 study demonstrated the successful development of the Weight and Emotions Scale (WES), a 16-item patient-reported outcome measure. Cognitive interviews with adults with obesity found that the scale was well-understood and effectively captured 13 emotion-related concepts relevant to weight management.
Evidence: moderate[7]Emerging pharmacotherapies for obesity: A systematic review.
A study published in Pharmacological reviews investigating the effects and mechanisms.
Evidence: moderate[8]Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
A study published in Metabolism: clinical and experimental investigating the effects and mechanisms.
Evidence: moderate[9]Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
A study published in Annals of internal medicine investigating the effects and mechanisms.
Evidence: moderate[10]Retatrutide-A Game Changer in Obesity Pharmacotherapy.
A study published in Biomolecules investigating the effects and mechanisms.
Evidence: preclinical[11]Gut hormones and appetite regulation.
A study published in Current opinion in endocrinology, diabetes, and obesity investigating the effects and mechanisms.
Evidence: preclinical[12]Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
A study published in Nature medicine investigating the effects and mechanisms.
Evidence: moderate[13]Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases.
A study published in CNS drugs investigating the effects and mechanisms.
Evidence: preclinical[14]The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
A study published in Metabolism: clinical and experimental investigating the effects and mechanisms.
Evidence: preclinical[15]Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions.
A study published in Gastroenterology report investigating the effects and mechanisms.
Evidence: preclinical[16]Weight management treatment in obesity.
A study published in Medicina clinica investigating the effects and mechanisms.
Evidence: preclinical[17]Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
A study published in Obesity (Silver Spring, Md.) investigating the effects and mechanisms.
Evidence: preclinical[18]The power of three: Retatrutide's role in modern obesity and diabetes therapy.
A study published in European journal of pharmacology investigating the effects and mechanisms.
Evidence: preclinical[19]Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
A study published in Endocrine reviews investigating the effects and mechanisms.
Evidence: preclinical[20]Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies.
A study published in The Kaohsiung journal of medical sciences investigating the effects and mechanisms.
Evidence: preclinicalSafety Profile
GI side effects (nausea, diarrhea) common; investigational not FDA-approved as of 2026. Phase 3 TRIUMPH trials ongoing.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea | ~36–60% (dose-dependent) | moderate |
| Diarrhea | ~20–34% (dose-dependent) | mild |
| Vomiting | ~10–22% (dose-dependent) | moderate |
| Constipation | ~6–16% (dose-dependent) | mild |
Sourcing Retatrutide for Research
If you're looking to source Retatrutide for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
* Research vendor — verify your regional regulations before purchase.
Full Research Profile
Retatrutide — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.